Rotigotine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Rotigotine
- Pharmacist Assessment Report
- Rotigotine: From Parkinson’s Disease and Restless Legs Syndrome to Attention Deficit-Hyperactivity Disorder
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Rotigotine: From Parkinson’s Disease and Restless Legs Syndrome to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Rotigotine is a dopamine agonist delivered by transdermal patch, originally used to treat Parkinson’s disease and restless legs syndrome. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), but there are currently no registered clinical trials and only 3 indirect publications (none testing rotigotine in ADHD), so this remains a research question.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Restless legs syndrome and Parkinson’s disease (from the knowledge graph; no approved indication text is recorded in the Australian licence data) |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Rotigotine is a non-ergolinic dopamine agonist. It acts on dopamine receptors D1 to D5, with the highest affinity at D3, then D2 and D1, and has some activity at 5-HT1A and alpha2B adrenergic receptors. The data compiled for this report did not include a formal mechanism of action record, so this description draws on the model’s rationale notes.
ADHD is associated with dysregulated dopamine and noradrenaline signalling. One preclinical paper (PMID 34182128) describes how dopamine D4 receptors and alpha2A adrenoceptors form heteromers, which offers a plausible but indirect receptor-level link. Restless legs syndrome and ADHD are also frequently comorbid, which may partly explain the model’s prediction.
However, the link is weak. The restless legs papers do not show that rotigotine treats ADHD. Dopamine agonists are not an established ADHD treatment: standard therapy relies on stimulants and noradrenergic agents that raise synaptic dopamine and noradrenaline.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18656214 | 2008 | Review | Revue Neurologique | Overview of restless legs syndrome (affects 2 to 3% of people in Western countries); does not address ADHD treatment with rotigotine |
| 21476956 | 2011 | Review | Current Pharmaceutical Design | Review of pharmacological options for restless legs syndrome in children; relevant to the RLS-ADHD comorbidity only |
| 34182128 | 2021 | Preclinical/Mechanistic | Pharmacological Research | Dopamine D4 receptor variants form heteromers with alpha2A adrenoceptors, with implications for ADHD and impulse-control disorders; no rotigotine data |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11140H | Neupro | Transdermal patch 18 mg | Not recorded in the data compiled for this report |
Safety Considerations
- Knowledge-graph contraindication associations (not taken from label text): hypertensive disorder, hypertension, multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension and drug-induced dyskinesia.
- Drug Interactions: 51 interactions were identified. The 20 listed in detail are all rated Moderate. Main ones include:
- Opioids and related agents: morphine (including liposomal), codeine, opium, difenoxin, diphenoxylate
- Sedating antihistamines: promethazine, chlorpheniramine, cetirizine, brompheniramine, carbinoxamine, clemastine, azelastine (nasal)
- Cannabinoids: dronabinol, nabilone
- Others: metoclopramide, ethanol, dextromethorphan, sibutramine, ioflupane I-123
Many of these involve additive central nervous system depression. Metoclopramide, a dopamine antagonist, may oppose rotigotine’s effect.
For label-based warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by indirect restless legs and receptor-pharmacology papers, with no trials of rotigotine in ADHD. Dopamine agonism is not an established ADHD mechanism, so the evidence remains at the model-prediction and mechanistic level (L4).
To proceed, the following is needed:
- A formal mechanism of action record for rotigotine
- Label-based warnings and contraindications from the TGA Product Information, to allow safety screening
- The approved indication text for the Australian ARTG entry
- Preclinical or early-phase clinical data of rotigotine in ADHD models or patients
- An assessment of whether a patch formulation and its dosing are suitable for the target population, including children
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.